Agent | Splenomegaly1 | Anemia2 | Symptoms3 | References |
---|---|---|---|---|
IMiDs | ||||
Thalidomide | 19 % | 43 % | NS | [15] |
(Celgene Corp., Summit, NJ, USA) | 8 % | 22 % | NR | [16] |
Lenalidomide | 10 % | 19 % | NR | [48] |
(Celgene Corp., Summit, NJ, USA) | 42 % | 30 % | NR | [18] |
Pomalidomide | 0 | ≤40 % | NR | [21] |
(Celgene Corp., Summit, NJ, USA) | 11 % | 37 % | NR | [22] |
0 | 17 % | NR | [23] | |
JAK Inhibitors | ||||
Ruxolitinib (INCB018424) | 44 % | 14 % | 52–82 % | [42] |
(Incyte Corporation, Wilmington, DE, USA—US rights; Novartis AG, Basel, Switzerland—ex-US rights) | 42 %4 | NR | 46 %5 | [43] |
32 %5 | NR | NR | [44] | |
SAR302503 (TG101348) (Sanofi, Paris, France) | 39 % | 0 | 25–89 % | [47] |
CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada) | 45 | 50 % | NR | [49] |
Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore) | 44 % | <1 % | NR | [50] |
Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA) | 18 % | 1 % | NR | [51] |
mTOR Inhibitor | ||||
Everolimus (RAD001) (Novartis AG, Basel, Switzerland) | 17 % | <1 % | 69 %5 | [52] |